314761-14-3 Usage
Uses
Used in Pharmaceutical Industry:
(Z)-5-phenyl-2-(4-phenylthiazol-2-yl)-4-(2-(thiazol-2-yl)-hydrazono)-2,4-dihydro-3H-pyrazol-3-one is used as a potential therapeutic agent for various medical conditions due to its possible anti-inflammatory, antimicrobial, or antifungal properties. The presence of thiazole and pyrazolone rings in its structure may contribute to its bioactivity, making it a candidate for the development of new drugs.
Used in Agricultural Industry:
In the agricultural sector, (Z)-5-phenyl-2-(4-phenylthiazol-2-yl)-4-(2-(thiazol-2-yl)-hydrazono)-2,4-dihydro-3H-pyrazol-3-one may be utilized as a bioactive compound with potential antimicrobial or antifungal applications. Its use could be explored for the development of new pesticides or fungicides to protect crops from diseases and pests, thereby enhancing agricultural productivity.
Used in Industrial Applications:
The industrial applications of (Z)-5-phenyl-2-(4-phenylthiazol-2-yl)-4-(2-(thiazol-2-yl)-hydrazono)-2,4-dihydro-3H-pyrazol-3-one could include its use as a chemical intermediate in the synthesis of other complex organic compounds or as a component in various chemical formulations. Its unique structure and potential bioactivity may also find use in the development of new materials with specific properties for various industrial processes.
Check Digit Verification of cas no
The CAS Registry Mumber 314761-14-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,4,7,6 and 1 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 314761-14:
(8*3)+(7*1)+(6*4)+(5*7)+(4*6)+(3*1)+(2*1)+(1*4)=123
123 % 10 = 3
So 314761-14-3 is a valid CAS Registry Number.
314761-14-3Relevant academic research and scientific papers
HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells
Liang, Tao,Zhou, Yi,Elhassan, Reham M.,Hou, Xuben,Yang, Xinying,Fang, Hao
, p. 12083 - 12099 (2020/11/02)
Inspired by the synergistic effect of BTSA1 (a Bax activator) and SAHA (a histone deacetylase (HDAC) inhibitor) in HeLa cell growth suppression, a series of novel HDAC-Bax multiple ligands were designed rationally. Compound 23, which possesses similar HDAC inhibitory activity relative to SAHA and Bax affinity comparable to BTSA1, exhibits a superior growth suppression against HeLa cells, and its antiproliferative activities are 15-fold and 3-fold higher than BTSA1 and SAHA, respectively. The better antiproliferative activity and lower cytotoxicity of compound 23 indicated that our HDAC-Bax multiple ligand design strategy achieved success. Further studies suggested that compound 23 could enhance Bax-dependent apoptosis by upregulating Bax, followed by inducing the conformational activation of Bax. To our knowledge, we first report HDAC-Bax multiple ligands and demonstrate a new paradigm for the treatment of solid tumors by enhancing Bax-dependent apoptosis.
BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY
-
, (2019/01/05)
Activators of BAX and their uses in cancer therapy are disclosed.
